Molecular Genetic Alterations, Pathology and Clinical Prognosis in Oligodendroglial Tumors

HE Jie,QIAO Ying-juan,ZHENG Sheng-qin,YAO Qing,GUO Qing-ming,WEI Xiao-ying,HUANG Pei-lin

DOI: https://doi.org/10.3969/j.issn.1001-7399.2006.06.009

2006-01-01

Experimental Pathology

Abstract:Purpose To investigate the correlation of the molecular profile and pathology with clinical prognosis in oligodendroglial tumors. Methods A total of 26 cases of pure oligodendrogliomas and 25 glioblastomas with an oligodendroglial component (GBMO) were analyzed in this study. The DNA was extracted from the tumor tissues and peripheral blood. Denaturing gradient gel electrophoresis (DGGE) and DNA sequencing were used to detect the mutations of TP53, PTEN/MMAC1, and p18 tumor suppressor gene. Competitive multiplex PCR was conducted to detect the homozygous deletion of the p16/CDKN2A, p18 gene and amplification of the EGFR. Results In 25 cases of oligodendrogliomas, TP53, PTEN/MMAC1, p18 mutations, EGFR amplification, and p16/CDKN2A homozygous deletion were observed in 1(4%), 0, 1(4%), 5(19.2%), and 7(27%) cases, respectively. In 25 cases of GBMO, TP53, p18 and PTEN/MMAC1 mutations were detected in 24%, 0 and 20%; EGFR amplification in 44%, p16/CDKN2A homozygous deletions in 48% respectively. p18 was normally expressed in all of oligodendroglial tumors. Conclusions Oligodendrogliomas are characterized by rare present of TP53 and PTEN/MMAC1 mutation. The study demonstrates the unfavorable impact of EGFR amplification on the prognosis.